Repligen (NASDAQ:RGEN) Earns “Buy” Rating from HC Wainwright

Repligen (NASDAQ:RGEN)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $180.00 target price on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 10.65% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. TD Cowen began coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $183.36.

Repligen Price Performance

Shares of RGEN stock opened at $162.67 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market capitalization of $9.11 billion, a price-to-earnings ratio of -439.64, a PEG ratio of 4.23 and a beta of 0.99. The stock’s 50-day simple moving average is $155.17 and its 200-day simple moving average is $148.81.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. As a group, equities analysts forecast that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several large investors have recently made changes to their positions in the company. UMB Bank n.a. grew its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the period. First Turn Management LLC purchased a new stake in shares of Repligen during the 3rd quarter worth about $13,202,000. Thrivent Financial for Lutherans grew its position in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares during the period. Geneva Capital Management LLC grew its position in shares of Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after acquiring an additional 10,908 shares during the period. Finally, TimesSquare Capital Management LLC increased its stake in shares of Repligen by 14.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 275,627 shares of the biotechnology company’s stock valued at $41,019,000 after purchasing an additional 35,115 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.